Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 2,913 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Event Clear all

Conditions: Delirium, Delirium in Old Age, Critical Illness, Intensive Care Unit Delirium
Interventions: EyeControl-Pro, Control; Device · Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Colorectal Cancer
Interventions: FOLFOX (chemotherapy), 5 FUCMT (chemoradiation), surgery, magnetic resonance imaging or endorectal ultrasound; Drug · Other · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 1048
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 613 more

Conditions: Hyperkalemia
Interventions: Sodium Zirconium Cyclosilicate (SZC), SZC Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 2,690 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 57
States / cities: Huntsville, Alabama • Mesa, Arizona • Bakersfield, California + 47 more

Conditions: Thymic Epithelial Tumor, Recurrent Thymoma, Thymic Cancer
Interventions: PT-112; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Depression
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 7 Years to 11 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Long Beach, California • Atlanta, Georgia • Plano, Texas

Conditions: Cardiac Arrest
Interventions: scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing; Behavioral
Lead sponsor: Valleywise Health; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV, Drug-Induced Colitis, Drug Toxicity, Immune-related Adverse Event
Interventions: Infliximab, Methylprednisolone, Prednisone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: PTSD, Concussion, Mild
Interventions: SMART-CPT, CPT; Behavioral
Lead sponsor: San Diego Veterans Healthcare System; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Diego, California

Conditions: Mycosis Fungoides
Interventions: Valchlor; Drug
Lead sponsor: Helsinn Therapeutics (U.S.), Inc; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 36
States / cities: Little Rock, Arkansas • Duarte, California • La Mesa, California + 28 more

Conditions: End Stage Renal Disease
Interventions: NexSite HD Patients; Device
Lead sponsor: Marvao Medical; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 6
States / cities: Greenville, North Carolina • New Bern, North Carolina • Raleigh, North Carolina + 3 more

Conditions: Obstructive Sleep Apnea of Adult
Interventions: SleepWell24 Application, Usual Care Plus Activity Monitor; Behavioral · Other
Lead sponsor: Arizona State University; Other
Eligibility: 21 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Healthy Adult, Fitness Testing, Athlete, Aging, Exercise Physiology, Human Performance
Interventions: There is no intervention.; Other
Lead sponsor: VO Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Obesity
Interventions: Wellness Engagement Program; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 12 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Melanoma, Malignant Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
Interventions: therapeutic conventional surgery, laboratory biomarker analysis, Axitinib, pharmacological study; Procedure · Other · Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Orange, California

Conditions: Chronic Low Back Pain, Posttraumatic Stress Disorder
Interventions: Progressive exercise training, Waitlist Control; Behavioral
Lead sponsor: Boston University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Jamaica Plain, Massachusetts

Conditions: Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
Interventions: Valbenazine Oral Capsule; Drug
Lead sponsor: Stephen Ruedrich; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Transcranial Electrical Stimulation (tES)
Interventions: Transcranial electrical stimulation (tES) including SHAM; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 45 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Sepsis
Interventions: Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure, Midazolam, Volitional Measurement of Maximal Inspiratory Pressure (MIP), Inspiratory Muscle Strength Training (IMST), SHAM Inspiratory Muscle Strength Training (IMST), Diaphragm thickness measurement, Blood and Urine samples; Procedure · Drug · Device + 1 more
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Anaemia, Aspergillosis, Allergic Bronchopulmonary
Interventions: Daprodustat, rhEPO, Placebo, Iron therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 2,964 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 126
States / cities: Huntsville, Alabama • Pine Bluff, Arkansas • Anaheim, California + 103 more

Conditions: Cancer, Lung, Metastasis
Interventions: Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR); Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Type 2 Diabetes
Interventions: Tirzepatide, Dulaglutide, Semaglutide; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years and older
Enrollment: 70,000 participants
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes
Interventions: integrated program of nutrition, activity, behavior, and promotion; Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 10 Years to 16 Years
Enrollment: 4,603 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 8
States / cities: Irvine, California • Rockville, Maryland • Chapel Hill, North Carolina + 5 more

Conditions: Primary Biliary Cirrhosis
Interventions: Moexipril; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Aortic Valve Replacement
Interventions: Subjects previously implanted with INSPIRIS RESILIA Model 11500A and are undergoing planned valve-in-valve treatment.; Diagnostic Test
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028 – 2031
U.S. locations: 7
States / cities: Los Angeles, California • Gainesville, Florida • Orlando, Florida + 4 more

Search by objective public record fields.

Eyecontrol coMmunication Platform for dEliRium manaGemEnt in Intensive Care Units (EMERGE)

PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

PT-112 in Subjects With Thymoma and Thymic Carcinoma

Vortioxetine to Prevent Return of Symptoms in Children With Depression

MIHS Emergency Department CPR Quality Improvement Project

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

SMART-CPT for PTSD/Concussion Implementation

Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma

Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter

SleepWell24: An Innovative Smartphone Application to Improve PAP Adherence

Molecular Indicators of Systematic Fitness

Wellness Engagement Project, Petersburg

Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma

Exercise Maintenance in Chronic Pain and PTSD

Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities

Cognitive Enhancement Through Model-based and Individualized Neurostimulation

Project 4A: Inspiratory Muscle Training and Diaphragm Strength

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung

Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

Middle-School Based Primary Prevention Trial of Type 2 Diabetes

Moexipril for Primary Biliary Cirrhosis

INSPIRIS RESILIA Aortic Valve, Valve-in-Valve Surveillance Study